Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Washington Drug Letter > FDA Approves First Combo Drug for Type 2 Diabetes, Cholesterol

Washington Drug Letter

Oct. 17, 2011 | Vol. 43 No. 41

FDA Approves First Combo Drug for Type 2 Diabetes, Cholesterol

The FDA has approved Merck’s Juvisync, the first combination drug to treat Type 2 diabetes and cholesterol in one daily-dose tablet.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

Merck Ends Trials For Once-Promising Parkinson’s Drug Actavis Buys Warner Chilcott In $8.5B All-Stock Purchase Two New Chiefs Top List of Restructuring at FDA’s IT Office House Committee Probes FDA Official’s Departure

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.